Divigel
NDC Package 68025-083-07
Package Information
Divigel (estradiol) gel is a medication a female hormone (estrogen). This formulation utilizes a gel delivery system. Marketed by Vertical Pharmaceuticals, Llc, this product is identified by NDC 68025-083 and is authorized under FDA application NDA022038.
Identification & Billing
- RxCUI: 2619677 - estradiol 0.1 % (0.25MG / 0.25GM) Transdermal Gel
- RxCUI: 2619677 - 250 MG estradiol 0.001 MG/MG Topical Gel
- RxCUI: 2619677 - estradiol 0.1 % Transdermal Gel, 0.25 GM
- RxCUI: 2619678 - Divigel 0.1 % (0.25MG / 0.25GM) Transdermal Gel
- RxCUI: 2619678 - 250 MG estradiol 0.001 MG/MG Topical Gel [Divigel]
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 68025 - Vertical Pharmaceuticals, Llc
- 68025-083 - Divigel
- 68025-083-07 - 7 PACKET in 1 CARTON / .75 g in 1 PACKET
- 68025-083 - Divigel
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (68025-083). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 68025-083-07 identifies a specific commercial package of 7 packet in 1 carton / .75 g in 1 packet of Divigel, a human prescription drug labeled by Vertical Pharmaceuticals, Llc. This gel is formulated for topical use and contains estradiol as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Vertical Pharmaceuticals, Llc on January 18, 2019. The current certification is valid through December 31, 2027.
What are the primary indications for this medication?
This medication is a female hormone (estrogen). It is absorbed through the skin and enters into the bloodstream. It is used by women to help reduce a certain symptom of menopause (hot flashes). Symptoms of menopause are caused by the body making less estrogen. If you are using estrogens to treat only vaginal symptoms of menopause (such as vaginal dryness/burning/itching), products applied directly inside the vagina should be considered before medications that are taken by mouth, absorbed through the skin, or injected.
How is this Vertical Pharmaceuticals, Llc product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 68025008307. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.